C4 Therapeutics director takes 4,618 shares over cash
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
C4 Therapeutics Director Donna Roy Grogan received 4,618 shares of the company's common stock on October 1, 2026, as compensation instead of cash director fees. The shares were valued at $3.14 each, aligning with the closing price on that date. Following this transaction, Grogan directly owns 79,471 common shares of C4 Therapeutics (NASDAQ:CCCC).
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.